EP1404702A4 - Proteines secretees humaines - Google Patents

Proteines secretees humaines

Info

Publication number
EP1404702A4
EP1404702A4 EP02759068A EP02759068A EP1404702A4 EP 1404702 A4 EP1404702 A4 EP 1404702A4 EP 02759068 A EP02759068 A EP 02759068A EP 02759068 A EP02759068 A EP 02759068A EP 1404702 A4 EP1404702 A4 EP 1404702A4
Authority
EP
European Patent Office
Prior art keywords
secreted proteins
human secreted
human
proteins
secreted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02759068A
Other languages
German (de)
English (en)
Other versions
EP1404702A2 (fr
Inventor
Craig A Rosen
Steven M Ruben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of EP1404702A2 publication Critical patent/EP1404702A2/fr
Publication of EP1404702A4 publication Critical patent/EP1404702A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP02759068A 2001-03-21 2002-03-19 Proteines secretees humaines Withdrawn EP1404702A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27734001P 2001-03-21 2001-03-21
US277340P 2001-03-21
US30617101P 2001-07-19 2001-07-19
US306171P 2001-07-19
US33128701P 2001-11-13 2001-11-13
US331287P 2001-11-13
PCT/US2002/009785 WO2002095010A2 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Publications (2)

Publication Number Publication Date
EP1404702A2 EP1404702A2 (fr) 2004-04-07
EP1404702A4 true EP1404702A4 (fr) 2009-07-08

Family

ID=27402891

Family Applications (7)

Application Number Title Priority Date Filing Date
EP02760994A Withdrawn EP1379132A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02723499A Withdrawn EP1379264A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02749512A Withdrawn EP1381622A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
EP02782476A Withdrawn EP1414845A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02780789A Withdrawn EP1423134A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
EP02799146A Withdrawn EP1390390A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02759068A Withdrawn EP1404702A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Family Applications Before (6)

Application Number Title Priority Date Filing Date
EP02760994A Withdrawn EP1379132A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines
EP02723499A Withdrawn EP1379264A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02749512A Withdrawn EP1381622A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par les humains
EP02782476A Withdrawn EP1414845A4 (fr) 2001-03-21 2002-03-19 Proteines humaines secretees
EP02780789A Withdrawn EP1423134A2 (fr) 2001-03-21 2002-03-19 Proteines secretees par l'homme
EP02799146A Withdrawn EP1390390A4 (fr) 2001-03-21 2002-03-19 Proteines secretees humaines

Country Status (4)

Country Link
EP (7) EP1379132A4 (fr)
AU (6) AU2002332391A1 (fr)
CA (7) CA2441417A1 (fr)
WO (7) WO2002102994A2 (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196164B2 (en) 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
CA2295474A1 (fr) 1997-07-08 1999-01-21 Human Genome Sciences, Inc. 123 proteines humaines secretees
US20040141975A1 (en) 1998-06-01 2004-07-22 Raitano Arthur B. Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU757698C (en) 1998-06-01 2004-04-08 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20060052321A1 (en) 2002-04-05 2006-03-09 Raitano Arthur B Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
EE200100372A (et) 1999-01-15 2002-10-15 Biogen, Incorporated TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks
US7335731B2 (en) 2000-07-25 2008-02-26 Genentech, Inc. PRO4332 polypeptides
EP1666490A3 (fr) * 2000-07-25 2006-11-02 Genentech, Inc. Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci
WO2002048370A2 (fr) 2000-10-31 2002-06-20 Diadexus, Inc. Compositions et methodes associees a des genes et a des proteines specifiques du colon
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
US7250495B2 (en) 2001-06-20 2007-07-31 Genentech, Inc. PRO20044 polypeptides
AU2002336446B2 (en) 2001-09-06 2008-03-06 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
US7097990B2 (en) 2001-10-12 2006-08-29 Astellas Pharma Inc. Method of screening cell death inhibitor
CN103536916B (zh) 2002-04-09 2016-08-17 比奥根Ma公司 用于治疗tweak相关病症的方法
AU2003900747A0 (en) * 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
WO2005019258A2 (fr) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions et methodes de traitement de maladies relatives au systeme immunitaire
PT2380985E (pt) * 2003-09-23 2014-03-26 Univ North Carolina Células que expressam a vitamina k epóxido reductase e sua utilização
DK2189523T3 (da) * 2003-10-14 2012-03-12 Baxter Int VKORC1 (vitamin K-epoxid-tilbageføringspolypeptid), et terapeutisk mål for coumarin og dets derivater
EP1714154A2 (fr) * 2004-02-03 2006-10-25 Bayer HealthCare AG Agents diagnostiques et therapeutiques pour des maladies associes a la glutamate carboxypeptidase (pgcp) plasmatique
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
NZ550816A (en) 2004-04-22 2009-12-24 Agensys Inc Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
PL1794174T3 (pl) 2004-09-01 2012-11-30 Dynavax Tech Corp Sposoby i kompozycje do hamowania wrodzonych odpowiedzi immunologicznych i autoodporności
EP1799850A4 (fr) * 2004-09-07 2009-02-11 Telethon Inst For Child Health Methode de diagnostic et/ou de prediction du developpement d'une affection allergique
EP2093297A3 (fr) * 2004-09-07 2009-11-18 Telethon Institute for Child Health Research Agents de traitement ou de prévention d'un trouble allergique
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
PT1853700E (pt) 2005-02-28 2013-01-14 Baxter Int Co-expressão recombinante da subunidade 1 da vitamina k epóxido redutase para melhorar a expressão de proteína dependente de vitamina
CA2601574C (fr) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Procedes et compositions pour la production de proteines actives dependantes de la vitamine k
WO2006122187A2 (fr) 2005-05-10 2006-11-16 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) * 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
CA2620809A1 (fr) * 2005-09-01 2007-03-08 Howard Florey Institute Of Experimental Physiology And Medicine Agents prophylactiques et therapeutiques et leur utilisation
GB0521488D0 (en) * 2005-10-21 2005-11-30 Ares Trading Sa Integral membrane protein
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
AU2007308792B2 (en) 2006-10-27 2013-01-24 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
WO2008057459A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
US8093222B2 (en) 2006-11-27 2012-01-10 Isis Pharmaceuticals, Inc. Methods for treating hypercholesterolemia
EP2142217B1 (fr) * 2007-03-27 2014-11-05 Merck Sharp & Dohme Corp. Procédé de détection de pcsk9 secrétée, autogénérée
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2009055076A2 (fr) 2007-10-26 2009-04-30 Dynavax Technologies Corporation Procédés et compositions pour inhiber les réponses immunitaires et l'auto-immunité
CA2707182C (fr) * 2007-11-30 2017-12-12 Siemens Healthcare Diagnostics Inc. Fragments de recepteur de l'adiponectine et leurs procedes d'utilisation
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
CN102596249A (zh) 2009-10-30 2012-07-18 默沙东公司 Ax1和ax189 pcsk9拮抗剂和变体
IN2012DN03824A (fr) 2009-10-30 2015-08-28 Merck Sharp & Dohme
MX338980B (es) 2010-06-16 2016-05-06 Dynavax Tech Corp Metodos de tratamiento utilizando inhibidores de tlr7 y/o tlr9.
GEP20156313B (en) 2010-09-22 2015-07-10 Alios Biopharma Inc Substituted nucleotide analogs
EP2655607A4 (fr) 2010-12-21 2014-05-14 Univ North Carolina Procédés et compositions pour la production de protéines actives dépendantes de la vitamine k
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (fr) 2012-03-22 2015-10-28 Alios Biopharma Inc Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9682218B2 (en) 2013-12-23 2017-06-20 Carefusion 2200, Inc. Pleurodesis device and method
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3048479A1 (fr) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Edition genique de pcsk9
SG11201909218RA (en) 2017-04-03 2019-11-28 Hoffmann La Roche Antibodies binding to steap-1
CN110719968A (zh) * 2017-06-22 2020-01-21 宝洁公司 包括水溶性层和气相沉积无机涂层的膜
CN110709174A (zh) 2017-06-22 2020-01-17 宝洁公司 包括水溶性层和气相沉积有机涂层的膜
GB2613457B (en) 2020-04-09 2023-12-06 Verve Therapeutics Inc Base editing of angptl3 and methods of using same for treatment of disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5858716A (en) * 1997-05-30 1999-01-12 Smithkline Beecham Corporation H2CAA71 polynucleotides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004140A1 (fr) * 1998-07-15 2000-01-27 Human Genome Sciences, Inc. 71 proteines humaines secretees
WO2002026931A2 (fr) * 2000-09-25 2002-04-04 Human Genome Sciences, Inc. 71 proteines humaines secretees

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HSU SHEAU YU ET AL: "Characterization of two LGR genes homologous to gonadotropin and thyrotropin receptors with extracellular leucine-rich repeats and a G protein-coupled, seven-transmembrane region", MOLECULAR ENDOCRINOLOGY, vol. 12, no. 12, December 1998 (1998-12-01), pages 1830 - 1845, XP002528150, ISSN: 0888-8809 *
LOH E D ET AL: "Molecular Characterization of a Novel Glycoprotein Hormone G-Protein-Coupled Receptor", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 282, no. 3, 6 April 2001 (2001-04-06), pages 757 - 764, XP003002810, ISSN: 0006-291X *

Also Published As

Publication number Publication date
EP1379264A4 (fr) 2009-07-08
EP1414845A4 (fr) 2009-07-08
WO2003038063A3 (fr) 2003-12-11
CA2441416A1 (fr) 2003-01-16
WO2002090526A2 (fr) 2002-11-14
EP1390390A4 (fr) 2009-07-08
EP1404702A2 (fr) 2004-04-07
WO2002095010A3 (fr) 2004-02-12
WO2002102993A2 (fr) 2002-12-27
EP1390390A2 (fr) 2004-02-25
WO2002102994A2 (fr) 2002-12-27
EP1414845A2 (fr) 2004-05-06
CA2441840A1 (fr) 2002-11-28
AU2002320013A1 (en) 2002-11-18
EP1381622A2 (fr) 2004-01-21
CA2441702A1 (fr) 2002-12-27
EP1379264A1 (fr) 2004-01-14
CA2441397A1 (fr) 2002-10-03
AU2002354719A1 (en) 2003-01-21
CA2441755A1 (fr) 2003-05-08
WO2003004622A2 (fr) 2003-01-16
WO2002095010A2 (fr) 2002-11-28
WO2002102993A3 (fr) 2004-03-25
WO2003038063A2 (fr) 2003-05-08
CA2441417A1 (fr) 2002-11-14
EP1379132A4 (fr) 2009-07-01
AU2002332391A1 (en) 2003-01-02
AU2002363296A1 (en) 2003-05-12
WO2003004622A3 (fr) 2004-02-19
CA2441832A1 (fr) 2002-12-27
WO2002090526A3 (fr) 2003-10-30
EP1379132A2 (fr) 2004-01-14
AU2002324424A1 (en) 2002-12-03
WO2002102994A3 (fr) 2003-07-24
AU2002326293A1 (en) 2003-01-02
EP1423134A2 (fr) 2004-06-02
WO2002076488A1 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
EP1390390A4 (fr) Proteines secretees humaines
EP1506398A4 (fr) Proteines secretees humaines
EP1181390A4 (fr) 27 proteines humaines secretees
EP1391209A4 (fr) Formulations de proteines
EP1175439A4 (fr) 49 proteines humaines secretees
EP1165827A4 (fr) 45 proteines humaines secretees
EP1159284A4 (fr) 33 proteines humaines secretees
EP1189917A4 (fr) 48 proteines humaines secretees
EP1368468A4 (fr) 83 proteines humaines secretes
EP1185543A4 (fr) 50 proteines humaines secretees
EP1173477A4 (fr) 49 proteines humaines secretees
EP1171460A4 (fr) 48 proteines secretees humaines
EP1165828A4 (fr) 50 proteines humaines secretees
EP1317471A4 (fr) 21 proteines humaines secretees
EP1404807A4 (fr) 20 proteines humaines secretees
EP1185285A4 (fr) 49 proteines secretees humaines
EP1322657A4 (fr) Proteines secretees humaines 22
EP1171626A4 (fr) Cinquante proteines humaines secretees
EP1322659A4 (fr) 21 proteines humaines secretees
EP1165591A4 (fr) 47 proteines humaines secretees
EP1165123A4 (fr) 48 proteines humaines secretees
EP1181303A4 (fr) 50 proteines humaines secretees
EP1317467A4 (fr) 7 proteines humaines secretees
EP1187908A4 (fr) 42 proteines humaines secretees
EP1165590A4 (fr) 49 proteines humaines secretees

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031021

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/02 20060101ALI20090527BHEP

Ipc: C07K 1/00 20060101AFI20040219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090605

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090915